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ABSTRACT 
The use of natural supplements alongside prescribed medications is on the 
increase. Thus, it is important to analyze different properties of herbal supplements that 
can be implicated in eliciting herb-drug interactions. The herb Momordica charnatia is 
used throughout the world for its antidiabetic properties, and the herb Phyllanthus 
amarus is used in tropical and subtropical areas of the world for its hepatoprotective 
properties. Pregnane X Receptor (PXR) activation capabilities of these herbs was 
measured using a reporter gene assay. Additionally, Cytochrome P450 (CYP) isoform 
induction potential for CYP1A2, CYP3A4, CYP2B6, and CYP2C9 was determined 
through an enzymatic assay in hepatic cell line. M. charantia and P. amarus both 
increased PXR activity levels by a factor greater than two. Additionally, all four CYP 
isoforms were significantly induced by the herbs. These results indicate that when 
consumed concomitantly with conventional medicines both herbs may pose a risk of 
eliciting herb-drug interactions.   Further studies in more advanced models are warranted 
to determine the clinical relevance of these in vitro findings.   
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In 2012, a national survey was conducted in which it was revealed that greater 
than 30% of US adults used some form of complementary and alternative medicine 
(CAM)7. CAM includes but is not limited to acupuncture, meditation, Ayurveda, herbal 
medicine, and dietary supplements37. Natural products, classified as a dietary supplement 
that was not a vitamin or mineral, were found to be the most utilized CAM at 17.7%7. A 
separate study found that patients with chronic diseases as well as those who use over the 
counter drugs had an increased likelihood of using herbal supplements28. 
 Presently, the FDA’s regulation of herbal supplements is not as strict as the 
regulation of drugs. Herbal supplements are not required by law to meet the FDA’s safety 
requirements before they are marketed to the general public6. Therefore, the FDA is only 
legally able to act against companies once a product has reached the public and has been 
shown to induce illness or cause harm. Because of the prevalence of supplement usage 
alongside allopathic methods, it is critical to analyze the interactions between drugs and 
herbal supplements. One well-known example of an herb that demonstrates several herb-
drug interactions is St. John’s wort (Hypericum perforatum). This herb is commonly used 
in dietary supplements for treating anxiety and depression31. However, its use is 
associated with a reduction in the effectiveness of 
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the anti-coagulant drug warfarin as well as oral contraceptive pills through the induction 
of cytochrome P450 (CYP) enzymes3,26. By evaluating the effect of different supplements 
on the drug metabolizing enzymes and the pharmacokinetics of conventional drugs and 
disseminating this information to the general public, both consumers and practitioners 
can be more aware of the potential threats seemingly harmless herbs may pose to one’s 
dosing regimen.  
Two herbal supplements namely Phyllanthus amarus (P. amarus) and Momordica 
charantia (M. charantia) were selected for this study and evaluating their influence on 
the activity of major drug metabolizing enzyme CYP450 isoforms was the primary focus 
of this study. Pregnane X receptor (PXR) is a nuclear receptor that acts as a transcription 
factor and regulates the expression of genes responsible for drug metabolizing enzymes 
and transporters. Activation of PXR has been found to be responsible for clinically 
relevant pharmacological drug interactions due to an increase in the activity of major 
drug metabolizing enzymes such as CYP3A4 and CYP2C9 that results into enhanced 
clearance of drugs making them less effective15. Previous studies have shown that both 
herbal supplements, P. amarus and M. charantia, have a significant effect on the 
induction of PXR activity levels when tested at 60 µg/mL12. It is important to determine 
whether these results are indicative of either herb’s capability to induce the activity of 
drug metabolizing enzymes known to mediate herb-drug interactions. This will help in 
predicting the potential of these herbs to pose a risk of herb-drug interaction if they are 
consumed along with the prescription drugs for a long time (chronic exposure) or 
consumed in high quantities (acute exposure). 
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P. amarus, commonly known as ‘Carry Me Seed’, is popularly used as traditional 
medicine in tropical and subtropical parts of the world such as the Amazon, India, and 
Malaysia. It is used in ayurvedic medicine to confront an array of conditions associated 
with the stomach, kidney, spleen, and liver27. Additionally, P. amarus has been known to 
display hepatoprotective properties. Enogieru et al. (2015) found that in adult wistar rats 
the presence of P. amarus and the amount of liver damage suffered due to acetaminophen 
intake were negatively correlated.  
M. charantia also known as bitter melon, is consumed as a culinary item for its 
multitude of nutritious properties such as a high concentration of carotenoids19. 
Additionally, it is used alongside or instead of western medication for its perceived 
antidiabetic properties in parts of East Asia, East Africa, India, and South America18.  
Drugs and herbal supplements can be referred to as xenobiotics, defined by 
Dictionary.com as “a chemical or substance that is foreign to an organism or biological 
system.” The majority of xenobiotic metabolism occurs within the liver. The protein 
pregnane x receptor (PXR) has been highlighted alongside constitutive androstane 
receptor (CAR) as a xenobiotic sensing receptor present in the liver20. Because of the 
large, hydrophobic, and flexible ligand-binding domain, PXR is capable of being 
activated by a multitude of compounds leading to this being a major pathway of 
xenobiotic metabolism38.  It serves as a transcription factor for a large number of CYP 
enzymes including CYP2C9, CYP3A4, CYP2B633. PXR is activated following the 
binding of a ligand. Once the ligand activates PXR, the expression of CYP enzymes is 
induced21.   
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According to Horn and Hansten (2007), CYP enzymes are aggregated mainly in 
the liver and serve to synthesize molecules such as cholesterol and steroid hormones. 
Additionally, it has been shown that these enzymes serve to metabolize medications as 
well as autogenous toxins, and they are thought to be the leading mechanism through 
which pharmacokinetic interactions occur16.  These enzymes belong to the superfamily of 
monooxygenases and are of utmost importance during phase I of xenobiotic 
metabolism13. During this stage, the enzymes’ heme prosthetic group oxidizes 
hydrophobic compounds preparing the molecule for excretion32.  
CYP3A4, which aggregates in the small intestine in addition to the liver, is known 
as the CYP enzyme that metabolizes over 50% of drugs on the market34.  If a product 
tested were to inhibit this cytochrome, then it would increase plasma concentrations of 
drugs normally metabolized by said cytochrome17. On the other hand, if the product 
tested were to induce the cytochrome, then plasma concentrations of the drug would 
decrease. This would cause the drug to become less effective, thus requiring higher 
dosages to be prescribed.  These same processes could occur with the inhibition or 
induction of other key isoforms involved in drug metabolism such as CYP2B6, CYP2C9, 
and CYP1A2.  
Rifampicin, a drug used in the treatment of tuberculosis, is a well-known example 
of a CYP enzyme inducer4. Through the activation of PXR, it has been found to induce a 
variety of cytochromes including CYP2B6, CYP3A4, and CYP2C9. For these reasons, it 
was used as a positive control during this study. According to the World Health 
Organization, people with HIV are 16-27 times more likely to develop tuberculosis than 
those without HIV. With Rifampicin being a first-line drug in the treatment of 
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tuberculosis, many studies have been performed to determine its drug-drug interactions 
with antiretroviral treatment (ART)35. 
 An ART commonly used in the treatment of HIV is nevirapine, a non-nucleoside 
reverse transcriptase inhibitor (NNRTI)22. This drug is mainly metabolized through 
CYP3A4 with a small amount of metabolism by CYP2B6. Rifampicin induces CYP3A4 
to a greater extent than CYP2B6, and it has been shown that when used concomitantly 
with rifampicin, the plasma concentration levels of antiretroviral drug nevirapine undergo 
a significant reduction22. In one study, 21% to 38% of HIV/tuberculosis co-infected 
patients being treated with both rifampicin and nevirapine showed subtherapeutic 
nevirapine plasma concentration levels29. Additionally, rifampicin has been shown to 
increase clearance times of the blood thinner warfarin11. Three times higher dosage of the 
immunosuppressive drug cyclosporine is required when used concomitantly with 
rifampicin due to the subtherapeutic levels of regular dosage under these conditions.  
There are over fifty CYP enzyme isoforms, but most xenobiotics are metabolized 
through CYP3A4, CYP2D6, CYP2C9, CYP1A2, CYP2C8, CYP2C19, CYP2B6, and 
CYP2E19. This study was carried out to determine the effects of P. amarus and M. 
charantia on four major enzymes namely : CYP3A4, CYP1A2, CYP2B6, and CYP2C9 
which are responsible for the metabolism of a number of commonly consumed 
prescription drugs such as antiretroviral, anticoagulant, contraceptive, antidiabetic, and 
cardiovascular drugs.  
2 
 
2. MATERIALS AND METHODS 
2.1 Materials 
1. Cell Culture Medium  
a. This medium contained one packet of DMEM/F12 and 1% Pen-Strep 
purchased from Gibco as well as 2.4 g of sodium bicarbonate from Fisher. 
There was an addition of 10% fetal bovine serum (FBS) which was 
purchased from Atlanta Biologicals.  
2. No Serum Medium  
a. It was prepared in the same manner as the culture medium with the 
exception of the addition of FBS.  
3. Transfection Medium 
a. It was prepared in the same manner as the culture medium but contained 
2.5% FBS.  
4. Human hepatocellular carcinoma cells (HepG2)  
a. Purchased from the American Type Culture Collection (ATCC). As 
mentioned previously, the majority of xenobiotic metabolism occurs in the 
liver, thus it was most appropriate to use a liver cell line.  
5. 0.25% Trypsin   
a. 2.5 g Trypsin purchased from Gibco was combined with 0.3 g disodium 
salt EDTA and 1.0 g glucose both purchased from Sigma-Aldrich. 8.0 g of 
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b. NaCl, 0.4 g of KCl, and 0.58 g sodium bicarbonate (all purchased from 
Fisher) were also added into the mixture.  
6. Matrigel 
a. Purchased from Corning 
7. M. charantia extract (methanolic extract) 
8. P. amarus extract (methanolic extract) 
9. 10 mM Rifampicin  (Sigma -Aldrich) 
10. DMSO (Fisher) 
11. Promega P450-Glo Assay kits were used to detect the induction of CYP1A2, 
CYP3A4, CYP2B6, and CYP2C9 enzymatic activities. 
2.2 Maintenance of Cells 
HepG2 cells were retrieved from liquid nitrogen storage and thawed in a 37℃ 
water bath for about 1 minute. The outside of the vial containing the cells was disinfected 
using 70% ethanol, and then cells were transferred to a centrifuge tube. 9 mL of 
prewarmed culture medium was added to the 1 mL of cells in the centrifuge tube. Cells 
were centrifuged at 1000 rpm for 5 minutes. Once finished, the supernatant was 
discarded, and the cells were resuspended in 10 mL of culture medium and transferred to 
a culture dish pre-coated with Matrigel. The dish was incubated in a cell culture incubator 
at 37℃ in an atmosphere of 5% CO2 and 95% humidity. Twenty four hours later, the 
culture medium was replaced with fresh medium and cells were incubated further. Once 
the cells were confluent (about 4 to 5 days later) cells were trypsinized, resuspended in 
culture medium and plated in a 50 mL culture dish containing Matrigel. They were 
incubated at 37℃ with 5% CO2. Cells were subcultured twice a week once they reached 
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around 70% confluency in order to maintain integrity. Confluency was estimated by 
observing cells under a microscope. Subculturing consisted of five steps. The old culture 
medium was first removed from the culture dish. Cells were then dislodged from the 
Matrigel using 0.25% trypsin.  Once the trypsin was aspirated from the culture dish, cells 
were incubated in 37℃ until completely detached from the culture dish. While the cells 
were incubating, a new culture dish coated with Matrigel was filled with fresh culture 
medium. Finally, the cells were resuspended in culture medium, aliquoted, and added into 
a new culture dish containing Matrigel and fresh culture medium. Cells were incubated 
either for three to four days before the next subculture or until needed for use. 
2.3 Preparation of Plasmid DNA (PXR and PCR-5) 
 LB medium was made at a pH of 7.5 using 10 g of tryptone, 5 g of yeast, and 5 g 
of NaCl dissolved in 950 ml of Nanopure water. Medium was autoclaved at 121 ℃ for 15 
minutes and stored at 4℃. 10 mg/ml Ampicillin was added to LB medium to make LBA 
medium. LBA agar plates were made by adding 3.75 g of Bactoagar to 250 ml of LB 
medium. This solution was autoclaved at 121 ℃ for 15 minutes, cooled down to 45℃, 
and then 2.5 mL of 5 mg/ml ampicillin were added. Agar was poured into petri dishes 
and once solidified stored at 4℃. Ca2+ DH5-∂ cells were thawed and mixed. 100 ul of cell 
was placed in a 12 x 75 mm chilled snap cap tube. 10 ng of plasmid DNA was added to 
the tube, and cells with plasmid were incubated on ice for 30 minutes. Cells were then 
heat-shocked for 1 minute at 37℃ and placed on ice for 2 minutes. 900 ul of LB medium 
was added to the tube which was then shaken for four hours at 225 rpm. Transformed 
cells were then diluted and 100 ul of each dilution was spread on LBA plates which were 
incubated overnight at 37℃. Using a sterile inoculum loop, a colony was transferred 
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from the agar plate to a snap-cap tube that contained 4 ml LBA medium. This was done 
at least three times using different colonies. Overnight, the tubes were shaken at 37℃ at 
165 rpm. The tube with the greatest turbidity had l ml transferred to 3 sterile 1L flasks 
that contained 400 ml LBA medium. Flasks were shaken overnight at 180 rpm at 37℃. 
Each flask’s content was then centrifuged at 37 ℃ at 3000 rpm for 30 minutes in a 500 
ml plastic bottle. The pellet was retained.  
Isolation of plasmid DNA from the pellet of transformed E. Coli was carried out 
using a Qiagen Plasmid Purification Kit according to the instructions provided with the 
kit (www.qiagen.com/handbook" www.qiagen.com/handbook). Plasmid DNA was stored 
at 4oC and used for transfecting HepG2 cells. 
2.4 Plant Extracts Preparation 
The dried powders of leaves of M. charantia and the whole plant (root stem and 
leaves) of P. amarus from the National Center for Natural Products Research repository 
were extracted in methanol four times over a 24-hour time period in room temperature. 
Methanolic solutions were evaporated to complete dryness using a speed vacuum system. 
This yielded dried extracts. Extracts were then transferred to clean containers and stored 
in tightly closed glass vials. Solutions were prepared in DMSO to a concentration of 20 
mg/mL for the bioassays described below for PXR and CYPs activities. 
2.5 Transfection of Cells 
 HepG2 cells were subcultured into a new plate the day before beginning the 
assay. Cells were subcultured in a manner that ensured confluency the next day. On the 
first day of the assay, cells were transfected with human PXR (hPXR) and the luciferase 
reporter plasmid PCR512,23. First, the cells were trypsinized and placed in a 15 mL 
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centrifuge tube with 10 mL culture medium. 10 µL of the solution was placed in a cell 
counter slide. The slide was placed in an automated cell-counter in order to determine the 
cell concentration/mL.  Equation 1 was then used to determine the quantity of medium 
containing cells that would be needed for even distribution of about 50,000 cells/well in a 
96-well plate.  The calculated volume was then transferred to a new centrifuge tube. This 
solution was centrifuged for 5 minutes at 1000 rpm. The medium was then removed and 
replaced with 7 mL of DMEM/F12 medium (NS medium). Cells were resuspended in the 
medium, and the solution was centrifuged again for 5 minutes at 1000 rpm. The 
supernatant was removed, and the pellet was resuspended in 450 µL of transfection 
medium. 25 µg of hPXR and 25 µg of PCR5 were added to this solution. 
 After mixing, the solution was kept under the hood at room temperature for five 
minutes. The mixture was then transferred to an electroporation cuvette and transfected at 
180V for 70 msec using one pulse on an electroporator. The cuvette was then left 
untouched for 8 minutes under the hood. A transfer pipette was used to remove the foam 
from the cuvette, and the cells were mixed with the predetermined volume of culture 
medium needed for a full 96-well plate. A volume of 190 µL of the cell suspension was 
pipetted into each well of the sterile, white-bottomed polystyrene 96-well plate. In a 
sterile, clear polystyrene 96-well plate 200 µL of cell suspension was placed in 3 wells to 
watch for contamination during the rest of the week. Each plate was incubated at 37°C 
for 24 hours.  
2.7 Sample Addition 
A. PXR induction assay 
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During the second day of the assay, the positive control (Rifampicin), negative 
control (DMSO), Phyllanthus amarus (PA), and Momordica charantia (MC) extracts 
were added into the wells at varying concentrations based on a predetermined template. 
In the wells of a sterile, clear polystyrene plate, samples of PA and MC were serially 
diluted (3 fold) with no serum media. The five concentrations were 60, 20, 6.6, and 2.2, 
and 0.6 µg/mL. A 6% DMSO + NS medium solution was made and used for the dilution 
of the 20, 6.6, and 2.2, and 0.6 µg/mL samples. Each concentration was made in a 
different well. In the same plate, 30 µM of Rifampicin was made. The 96-well white-
bottomed polystyrene plate containing the transfected cells was retrieved from the 
incubator, and samples were added directly to the medium of their predetermined well. 
Each plate was again incubated for 24 hours at 37°C. 
B. CYP induction assay 
During the second and third days of the assay, the positive control (Rifampicin), 
negative control (DMSO), Phyllanthus amarus (PA), and Momordica charantia (MC) 
extracts were added into the wells at varying concentrations based on a predetermined 
template. In a sterile, clear polystyrene plate, the four concentrations of PA and MC 
samples were generated. The three concentrations were 30, 10, and 3.3 µg/mL. A 6% 
DMSO + NS medium solution was made and used for the dilution of the 10, 3.3, and 1.1 
µg/mL samples. Each concentration was made in a different well. In the same plate, 30 
µM of Rifampicin was made. Before adding the herbs and the controls, the medium was 
removed from each well without disrupting the cells and was replaced with 190 µL of 
serum medium.  10 µL of the samples, Rifampicin, and 6% DMSO were added to their 
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preset well. The clear control plate was checked for any signs of contamination. Each 
plate was incubated at 37°C for 24 hours.  
2.8 PXR induction assay data procurement  
 After transfection of cells and one day of sample addition, results were procured 
through the measurement of luminescence. Once the 24-hour incubation period was over, 
the medium was aspirated from each well and replaced with 40 µL of luciferase mix to 
each well. The plate was immediately placed in a Spectramax M5 plate reader for 
luminescence reading. Fold induction in the luciferase activity of sample treated cells was 
then calculated in comparison to DMSO-treated cells (vehicle control). 
2.8 CYP Induction assay data procurement  
After transfection of cells and two days of sample addition, results were procured 
through the measurement of luminescence. Preparation of the wells was dependent upon 
the enzyme that was being tested. For CYP3A4 and CYP2C9, the medium was removed 
from the well, and the well was washed one time with 100 µL of PBS.  In the CYP3A4 
wells, 50 µL of 2.5% luciferin PFBE + culture medium was added to each well. CYP2C9 
wells had 50 µL of 2.0% luciferin H + culture medium added to them. The plate was then 
incubated for 3 hours at 37°C. 40 µL of in house luciferase mix was added to each well 
after the incubation period, and the plate was read using a Spectramax M5 plate reader. 
Fold increase in luciferase activity was then calculated in sample treated cells in 
comparison to DMSO-treated cells (vehicle control).  
 For CYP2B6 and CYP1A2 enzymes, a 3 mM salicylamide solution in PBS was 
prepared. Once the salicylamide solution was prepared, the medium was removed from 
the wells. Wells were then washed two times with 50 µL of PBS. 50 µL 0.1% luciferin 
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2B6 + salicylamide solution was added into each of the CYP2B6 wells.  In the CYP1A2 
wells, 50 µL of  0.1% luciferin 1A2 +salicylamide solution was added. The cells being 
tested for CYP2B6 activity were incubated for 2 hours whereas those testing for the 
CYP1A2 activity were incubated for 1 hour. Once the incubation period for both 
enzymes was finished, 0.1% d-cysteine + luciferase mixture was made. 50 µL of this 
mixture was added into each well, and the plate was read using a Spectramax M5 plate 
reader. Fold increase in luciferase activity was then calculated in sample treated cells in 
comparison to DMSO-treated cells (vehicle control).  
2.9 Statistical Methods 
 GraphPad Prism 8 was used. One-way ANOVA was utilized in the analyzation of 
data. This was followed by Dunnett’s multiple comparison tests. Results were considered 








Figure 1: Diagrammatic representation of a Reporter Gene Assay (Karen Cohrt, 2018) 
Equation 1:𝐯𝐨𝐥𝐮𝐦𝐞 𝐨𝐟 𝐜𝐞𝐥𝐥𝐬 𝐧𝐞𝐞𝐝𝐞𝐝 (𝐦𝐋) = 
𝟐.𝟓×𝟏𝟎𝟓
𝐦𝐋








* = p < .05 
** = p <.01 
*** = p < .001 
**** = p < .0001 
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* = p < .05 
** = p <.01 
*** = p < .001 
**** = p < .0001 











Figure 2: PXR activation by M. charantia methanolic extract. Values were determined using a luciferase 











Figure 3: PXR activation by P. amarus methanolic extract. Values were determined using a luciferase gene 
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 Table 1: Comparison of PXR activation between M. charantia and P. amarus  














Figure 4: Increase in CYP3A4 enzyme activity by M. charantia methanolic extract in HepG2 cells. 







Test concentration M. charnatia P. amarus 
60 µg/mL 3.48 ± 1.65 3.44 ± 1.80 
20 µg/mL 2.28 ± 0.56 2.67 ± 1.41 
6.6 µg/mL 1.58 ± 0.13 1.84 ± 0.71 
3.3 µg/mL 1.24 ± 0.02 1.23 ± 0.30 
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** = p <.01 
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Figure 5: Increase in CYP2C9 activity by M. charantia methanolic extract. Rifampicin was the positive 














Figure 6: Increase in CYP2B6 activity by M. charantia methanolic extract in HepG2 cells. Rifampicin was 
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Figure 7: Increase in CYP1A2 activity by M. charantia methanolic extract in HepG2 cells. Rifampicin was 













Figure 8: Increase in CYP3A4 activity by P. amarus methanolic extract in HepG2 cells. Rifampicin was 
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Figure 9: Increase in CYP2C9 activity by P. amarus methanolic extract  in HepG2 cells. Rifampicin was the positive 
control. Data represents the mean ± SD. 
Figure 10: Increase in CYP2B6 activity by P. amarus methanolic extract in HepG2 cells. Rifampicin was the positive control. 







































































































* = p < .05 
** = p <.01 
*** = p < .001 








Figure 10: Increase in CYP1A2 activity by P. amarus methanolic extract in HepG2 cells. Rifampicin was 
the positive control. Data represents the mean ± SD.   
Figure 11: M. charantia 
(Sayat Arslanlioglu, 2008) 
 
Figure 12: P. amarus 
(Jim Conrad, 2019) 
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Table 2: CYP3A4 fold induction comparison between M. charantia and P. amarus 
 
Table 3: CYP2C9 fold induction comparison between M. charantia and P. amarus  
Test concentration M. charantia P. amarus 
30 µg/ml 14.97 ± 5.27 8.39 ± 1.69 
10 µg/ml 6.47 ± 2.02 2.67 ± 0.11 
3 µg/ml 2.55 ± 1.03 2.55 ± 0.42 
 
Table 4: CYP2B6 fold induction comparison between M. charantia and P. amarus  
Test concentration M. charantia P. amarus 
30 µg/ml 6.82 ± 3.68 4.81 ± 1.04 
10 µg/ml 5.06 ± 2.02 3.30 ± 0.85 
3 µg/ml 1.61 ± 0.11 2.36 ± 0.68 
 
Table 5: CYP1A2 fold induction comparison between M. charantia and P. amarus  
Test concentration M. charantia P. amarus 
30 µg/ml 8.47 ± 3.87 7.89 ± 1.71 
10 µg/ml 4.81 ± 3.22 5.54 ± 1.42 
3 µg/ml 1.27 ± 0.16 2.45± 1.09 
 
  
Test concentration M. charantia P. amarus 
30 µg/ml 4.09 ± 0.72 3.14 ± 0.41 
10 µg/ml 4.06 ± 0.28 1.91 ± 0.35 
3 µg/ml 2.51 ± 0.02 1.41 ± 0.21 
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Increase in the activity of major CYP enzymes has been implicated in affecting 
the pharmacokinetics of several drugs which are the substrates of CYP isoforms. Herbs 
such as St. John’s wort and foods such as grapefruit juice are examples of naturally 
occurring substances that can cause the reduction in drug-efficacy and/or produce life-
threatening side effects when taken concomitantly with a variety of prescription drugs 
due to pharmacokinetic interactions25. In areas of the world with low access to medicinal 
solutions to diabetes, M. charantia has been said to be the most popular anti-diabetic 
herbal alternative18. P. amarus is used in various Asian countries as a treatment for 
hepatitis and jaundice14. It is also used as a liver tonic for maintenance of a healthy liver. 
Because of the widespread prevalence and use of these herbs, it is important to determine 
the likelihood for pharmacokinetic drug interactions if these herbs are concomitantly 
consumed with the prescription drugs.  
 In vitro studies utilizing human hepatocellular carcinoma cells were performed to 
analyze the PXR modulation and CYP induction capabilities of the two herbs. The results 
from a reporter gene assay to determine the modulation of PXR indicated that both herbs 
activated the PXR and increased its transcriptional activity at a level greater than two-
fold compared to vehicle control. These results are consistent with the results of an earlier 
study performed by Fasinu et al (2017). Increased PXR activity levels have been linked 
with the induction of cytochrome P450 enzymes23. Due to this positive correlation, M. 
charantia and P. amarus were tested for their CYP induction capabilities. When 
analyzing CYP induction capabilities, M. charantia showed significant induction of all 
four CYP enzymes. At all three concentration levels, M. charantia significantly induced 
CYP3A4 implying that this herb is most likely to impact that pharmacokinetics of drugs 
2 
 
that utilize this pathway. P. amarus also significantly induced all four CYPs. At 30 µg/ml 
and 10 µg/ml, M. charantia induced all four enzymes at a greater strength than P. 
amarus.  
 Both herbs significantly induced CYP3A4 similarly to St. John’s wort which has 
been shown to reduce the effectiveness of drugs that are substrates of CYP3A4 such as 
alprazolam24. It is likely that drugs taken concomitantly with the tested herbal 
supplements could experience a reduction in efficacy and in turn will need dosage 
alterations to maintain desired treatment levels. However, these two herbs have also 
demonstrated CYP inhibition properties as reported earlier by Fasinu et al (2017). P. 
amarus had inhibitory effects on all four enzymes tested in this study while M. charantia 
did not inhibit CYP2B6.  
A natural product with known CYP inhibitory effects is grapefruit juice2. Inhibitory 
effects are immediate and lead to an increase in drugs plasma concentration levels. In 
future studies, it is important to find out whether the inhibitory effects of the tested 
samples are reversible or not. This is important because the mechanism through which 
determines the length of the impact on the pharmacokinetics of other drugs. For example, 
grapefruit juice is partially irreversible thus the effects are relatively long-lasting2. It has 
been reported that when a drug is taken 12 hours after grapefruit juice ingestion, the rate 
that the drug enters systemic circulation doubles30.  
This capability of M. charantia and P. amarus to both inhibit and induce CYP 
isoforms is not contradictory. Conventional medicines are generated as isolated 
chemicals with a specific biochemical target in mind. Conversely, natural supplements 
have a unique composition of phytochemicals, thus enabling the herbs to impact different 
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biochemical targets and/or the same biochemical target in opposite manners15. In cases 
similar to that of M. charnatia and P. amarus, the net effect of the induction and 
inhibition of the same CYP isoform may be neutral and may not be significant enough to 
pose a clinically relevant risk. In vitro studies such as the one performed are only 
predictive of herb-drug interactions that can occur. In order to establish the final 
outcome, more advanced studies are warranted to establish an overall physiological 
effect.     
  
Figure 13: Herb-drug interaction through induction or inhibition of CYP 
450 Enzymes (Hogle et al, 2018) 






There is a lack of literature analyzing the impact of two herbs, M. charnatia and P. 
amarus, on the ability to induce different CYP isoforms. In this study, PXR activity 
levels and CYP induction capabilities were analyzed as a predictor of herb-drug 
interaction capabilities. Both M. charnatia and P. amarus were found to increase PXR 
activity levels and induce CYP3A4, CYP1A2, CYP2B6, and CYP 2C9. This shows the 
potential of M. charnatia and P. amarus to alter drug pharmacokinetics.  The in vitro 
studies performed are only predictive. Therefore, for a better understanding of the 
biochemical processes that will occur, further studies such as in vivo animal studies are 
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